MetLife Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6M | Buy |
109,161
+2,935
| +3% | +$161K | 0.04% | 507 |
|
|
2025
Q1 | $7.51M | Sell |
106,226
-1,177
| -1% | -$83.2K | 0.04% | 434 |
|
|
2024
Q4 | $7.06M | Buy |
107,403
+9,031
| +9% | +$594K | 0.04% | 389 |
|
|
2024
Q3 | $6.91M | Sell |
98,372
-1,597
| -2% | -$112K | 0.04% | 373 |
|
|
2024
Q2 | $8.23M | Buy |
99,969
+95,406
| +2,091% | +$7.85M | 0.05% | 289 |
|
|
2024
Q1 | $399K | Buy |
4,563
+12
| +0.3% | +$1.05K | ﹤0.01% | 1802 |
|
|
2023
Q4 | $439K | Sell |
4,551
-80
| -2% | -$7.71K | ﹤0.01% | 1769 |
|
|
2023
Q3 | $410K | Buy |
4,631
+6
| +0.1% | +$531 | ﹤0.01% | 1756 |
|
|
2023
Q2 | $401K | Buy |
4,625
+803
| +21% | +$69.6K | ﹤0.01% | 1847 |
|
|
2023
Q1 | $372K | Buy |
3,822
+8
| +0.2% | +$778 | ﹤0.01% | 1834 |
|
|
2022
Q4 | $395K | Buy |
3,814
+18
| +0.5% | +$1.86K | ﹤0.01% | 1795 |
|
|
2022
Q3 | $322K | Sell |
3,796
-92
| -2% | -$7.8K | ﹤0.01% | 1957 |
|
|
2022
Q2 | $322K | Buy |
3,888
+241
| +7% | +$20K | ﹤0.01% | 1973 |
|
|
2022
Q1 | $281K | Buy |
+3,647
| New | +$281K | ﹤0.01% | 2132 |
|
|
2019
Q2 | – | Sell |
-242
| Closed | -$21.5K | – | 2450 |
|
|
2019
Q1 | $21.5K | Buy |
242
+1
| +0.4% | +$89 | ﹤0.01% | 2339 |
|
|
2018
Q4 | $20.5K | Sell |
241
-2
| -0.8% | -$170 | ﹤0.01% | 2339 |
|
|
2018
Q3 | $23.6K | Buy |
+243
| New | +$23.6K | ﹤0.01% | 2374 |
|